Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) EPS (Basic) (2016 - 2023)

RedHill Biopharma has reported EPS (Basic) over the past 12 years, most recently at $0.09 for Q2 2023.

  • Quarterly EPS (Basic) rose 350.0% to $0.09 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $0.09 through Dec 2024, up 145.0% year-over-year, with the annual reading at $0.05 for FY2025, 7823.56% up from the prior year.
  • EPS (Basic) was $0.09 for Q2 2023 at RedHill Biopharma, up from -$0.05 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $0.09 in Q2 2023 and troughed at -$0.37 in Q4 2021.
  • The 5-year median for EPS (Basic) is $0.04 (2019), against an average of $0.0.
  • Year-over-year, EPS (Basic) plummeted 628.57% in 2021 and then skyrocketed 350.0% in 2023.
  • A 5-year view of EPS (Basic) shows it stood at $0.03 in 2019, then skyrocketed by 133.33% to $0.07 in 2020, then crashed by 628.57% to -$0.37 in 2021, then soared by 35.14% to -$0.24 in 2022, then surged by 137.5% to $0.09 in 2023.
  • Per Business Quant, the three most recent readings for RDHL's EPS (Basic) are $0.09 (Q2 2023), -$0.05 (Q1 2023), and -$0.24 (Q4 2022).